Science News
Stay updated with the latest scientific news and research. Read press releases covering groundbreaking discoveries, innovations, and developments across various scientific fields. Keep up with the advancements and insights shaping the future of science.
May 25, 2026 at 4:16 AM
JEOL: Sales Launch of the Laser SEM System “LazEdge”
TOKYO--(BUSINESS WIRE)--JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-qu...
May 25, 2026 at 2:00 AM
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease
BORDEAUX, France--(BUSINESS WIRE)--TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. Th...
May 22, 2026 at 10:16 AM
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
WILMINGTON, Del.--(BUSINESS WIRE)--May 22, 2026 — AstraZeneca and Daiichi Sankyo’s DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval follows Priority Review by the Food and Drug Administration (FDA) based on results from the TROPION-Breast02 Phase III trial which were presented at the 2025 European Societ...
May 22, 2026 at 8:30 AM
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of...
May 22, 2026 at 8:00 AM
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal i...
May 22, 2026 at 8:00 AM
Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 9500 Triple Quadrupole ICP-MS, a next-generation inductively coupled plasma mass spectrometry system designed to help single quadrupole ICP-MS laboratories more easily transition to triple quadrupole technology for advanced trace elemental analysis. As testing demands grow more complex and skilled resources remain limited, laboratories face increasing pressure to deliver faster, i...
May 22, 2026 at 7:00 AM
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death and transform outcomes for people living with rare diseases with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2, 2026. More than 85 abstracts will feature 10 approved and 13 potential new medicines from the Company, including 25 oral presentations. Highlights include: EMERALD-3: Pha...
May 22, 2026 at 7:00 AM
Foundation Medicine Showcases Innovation at 2026 ASCO® Annual Meeting
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2 in Chicago. Data from 14 abstracts will be presented on copy number loss detection, serial circulating tumor DNA (ctDNA) genomic profiling, Foundation Medicine’s proprietary...
May 22, 2026 at 7:00 AM
SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026
MORRISVILLE, N.C.--(BUSINESS WIRE)--SAGA will present new data supporting Pathlight, its tumor-informed, structural variant-based ctDNA platform, across metastatic and localized cancers....
May 22, 2026 at 1:00 AM
Outcome of Innate Pharma’s 2026 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma’s 2026 Annual General Meeting...
Media & Journalist Tools
From headlines to storylines—Business Wire delivers the news you need, when you need it.